Introduction: Several malaria vaccines are under various phases of development with some
promising results. In placental malaria (PM) a deliberately anti-disease approach is …

Introduction: Placental malaria (PM) is a major public health problem that constitutes a
significant health concern for the mother, and especially for the developing fetus and …

VAR2CSA is a leading candidate for developing a placental malaria (PM) vaccine that
would protect pregnant women living in malaria endemic areas against placental infections …

Placental malaria (PM) due to Plasmodium falciparum is a major cause of maternal, fetal
and infant mortality, but the mechanisms of pathogenesis and protective immunity are …

Plasmodium falciparum-infected erythrocytes (IE) sequester in the placenta via surface
protein VAR2CSA, which binds chondroitin sulfate A (CSA) expressed on the …

Background VAR2CSA is the lead antigen for developing a vaccine that would protect
pregnant women against placental malaria. A multi-system feasibility study has identified E …

Placental malaria (PM) is a deadly syndrome most frequent and severe in first pregnancies.
PM results from accumulation of Plasmodium falciparum-infected erythrocytes (IE) that …

The disease caused by Plasmodium falciparum (Pf) involves different clinical manifestations
that, cumulatively, kill hundreds of thousands every year. Placental malaria (PM) is one such …

Two vaccines based on Plasmodium falciparum protein VAR2CSA are currently in clinical
evaluation to prevent placental malaria (PM), but a deeper understanding of var2csa …

VAR2CSA is the Plasmodium falciparum variant surface antigen that mediates binding of
infected erythrocytes to chondroitin sulfate A (CSA) and their sequestration in intervillous …